AlphaQuest LLC Sells 2,724 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

AlphaQuest LLC decreased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 35.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,862 shares of the company’s stock after selling 2,724 shares during the period. AlphaQuest LLC’s holdings in Amphastar Pharmaceuticals were worth $181,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after purchasing an additional 871 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after purchasing an additional 398 shares during the last quarter. KBC Group NV grew its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 90.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock valued at $156,000 after purchasing an additional 1,992 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock opened at $26.66 on Monday. The firm has a market cap of $1.27 billion, a PE ratio of 8.89, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 12-month low of $25.89 and a 12-month high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company’s fifty day simple moving average is $32.73 and its two-hundred day simple moving average is $41.19.

Wall Street Analyst Weigh In

Several research firms recently commented on AMPH. Piper Sandler lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.